ELUT vs XTNT

For growth investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus -49. 6% for Elutia Inc. (ELUT). Elutia Inc. (ELUT) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Xtant Medical Holdings, Inc.

(XTNT) delivered a total return of -66. 1%, compared to -91. 4% for Elutia Inc. (ELUT). Over 10 years, the gap is even starker: ELUT returned -93. 1% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elutia Inc.

(ELUT) is the lower-risk stock at -0. 11β versus Xtant Medical Holdings, Inc. 's 0. 69β — meaning XTNT is approximately -747% more volatile than ELUT relative to the S&P 500. On balance sheet safety, Elutia Inc. (ELUT) carries a lower debt/equity ratio of 27% versus 82% for Xtant Medical Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xtant Medical Holdings, Inc.

(XTNT) is pulling ahead at 28. 4% versus -49. 6% for Elutia Inc. (ELUT). Over a 3-year CAGR, XTNT leads at 28. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elutia Inc.

(ELUT) is the more profitable company, earning 434. 2% net margin versus -14. 0% for Xtant Medical Holdings, Inc. — meaning it keeps 434. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XTNT leads at -10. 3% versus -149. 8% for ELUT. At the gross margin level — before operating expenses — XTNT leads at 58. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Elutia Inc.

(ELUT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Both have compounded well over 10 years (ELUT: -93. 1%, XTNT: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELUT is a small-cap deep-value stock; XTNT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.